The key strength of the formulation research and development is the turnaround time taken from R&D to patients. This is led by a strong understanding of clinical and regulatory pathways.
Attributed with many firsts to introduce pharmaceutical products such as dapoxetine, troxipide and ferric carboxymaltose and a range of chiral molecules such as S-amlodipine, S-metoprolol and s-atenolol
In the process of developing novel drug delivery systems based on the liposomal and nanotechnology platforms. Also identified several antifungal, antibiotic and oncology products that will be developed using these platforms
Effectively developed and marketed 11 chiral molecules which have demonstrated greater efficacy , safety and require lesser dosage than their non-chiral counterparts